Regulatory issues

Field trials in USA in 2014, 2015.

Food Addit­ives:
GRAS status for our first colicin products in 2015 (GRN593), 2017 (GRN676) and 2018 (GRN775), and thau­matin sweetener (GRN738); several GRAS applic­a­tions are being filed in 2018.

GMP certi­fic­a­tion of the facility in Halle, Germany (divested with ICON); successful Phase I trials in USA with NHL cancer vaccine; Phase I-II with ZMapp anti-Ebola therapy (based on our tech­no­logy).

Clear regu­latory path for products based on our propri­etory manu­fac­turing process.